Prof Lloyd Sansom

Prof Lloyd Sansom

School of Pharmacy and Biomedical Science

College of Health

Available For Media Comment.

Year Citation
2024 Ollendorf, D., Henshall, C., Phillips, M., Synnott, P., Sansom, L., & Tunis, S. (2024). Putting meat on the bone: how to fast-track innovative medicines to those who need them and generate data to justify continued use. Health Affairs Scholar, 2(8, article no. qxae095), 1-5.
DOI
2024 Phillips, M., Synnott, P., Henshall, C., Tunis, S., Sansom, L., & Ollendorf, D. (2024). Towards a coordinated approach for managing accelerated patient access to potentially beneficial medicines: reporting the perspectives of a multi-stakeholder, international workshop. Health Affairs Scholar, 2(6, article no. qxae069), 1-9.
DOI
2021 Latimer, N. R., Pollard, D., Towse, A., Henshall, C., Sansom, L., Ward, R. L., . . . Deakin, C. (2021). Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop. BMC Health Services Research, 21(1, article no. 412), 1-9.
DOI
2021 Howe, K., Bourke, S., & Sansom, L. (2021). The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: a scoping review. PLoS ONE, 16(12, article no. e0261022), 1-17.
DOI
2017 Wale, J., Scott, A. M., Hofmann, B., Garner, S., Low, E., & Sansom, L. (2017). Why patients should be involved in health technology assessment. International journal of technology assessment in health care, 33(1), 1-4.
DOI
2016 Henshall, C., Latimer, N. R., Sansom, L. N., & Ward, R. L. (2016). Treatment switching in cancer trials: Issues and proposals. International journal of technology assessment in health care, 32(3), 167-174.
DOI
2014 Henshall, C., Sansom, L. N., Eichler, H. G., Lembruger, A., Longson, C., O'Rourke, B., & Tunis, S. (2014). Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: What are they looking for, and how and why does this differ from what regulators require?. Therapeutic innovation and regulatory science, 48(3), 341-346.
DOI
2013 Sansom, L. (2013). HTA and value: a commentary. International journal of technology assessment In health care, 29(4), 375-376.
DOI
2013 Juhasz, A. L., Smith, E. R. G., Weber, J., Rees, M., Kuchel, T., Rofe, A., . . . Naidu, R. (2013). Predicting lead relative bioavailability in peri-urban contaminated soils using in vitro bioaccessibility assays. Journal of environmental science and health, part A: toxic/hazardous substances and environmental engineering, 48(6), 604-611.
DOI Scopus36 WoS33 Europe PMC18
2010 Sansom, L. N. (2010). Assessing the value of medicines. Pharmaceutical medicine, 24(2), 89-92.
2009 Juhasz, A. L., Weber, J., Smith, E., Naidu, R., Rees, M., Rofe, A., . . . Sansom, L. (2009). Assessment of four commonly employed in vitro arsenic bioaccessibility assays for predicting in vivo relative arsenic bioavailability in contaminated soils. Environmental science and technology, 43(24), 9487-9494.
DOI Scopus190 WoS174 Europe PMC119
2009 Juhasz, A., Weber, J., Smith, E., Naidu, R., Marschner, B., Rees, M., . . . Sansom, L. (2009). Evaluation of SBRC-gastric and SBRC-intestinal methods for the prediction of in vivo relative lead bioavailability in contaminated soils. Environmental Science & Technology, 43(12), 4503-4509.
DOI Scopus124 WoS116 Europe PMC80
2009 Rees, M., Sansom, L., Rofe, A., Juhasz, A., Smith, E., Weber, J., . . . Kuchel, T. (2009). Principles and application of an in vivo swine assay for the determination of arsenic bioavailability in contaminated matrices. Environmental Geochemistry and Health, 31(Sp Iss 1), 167-177.
DOI Scopus53 WoS45 Europe PMC32
2009 Rahman, M., Rahman, F., Sansom, L., Naidu, R., & Schmidt, O. (2009). Arsenic interactions with lipid particles containing iron. Environmental Geochemistry and Health, 31(Sp Iss 1), 201-206.
DOI Scopus12 WoS11 Europe PMC9
2008 Wodak, A., Ali, R., Sansom, L., & Henry, D. (2008). Ensuring the safety of new medications and devices: are naltrexone implants safe?. Medical Journal of Australia, 188(8), 438-439.
DOI Scopus10 WoS8 Europe PMC3
2008 Juhasz, A. L., Smith, E. R. G., Weber, J., Naidu, R., Rees, M., Rofe, A., . . . Sansom, L. N. (2008). Application of an in vivo swine model for the determination of arsenic bioavailability in contaminated vegetables. Chemosphere, 71(10), 1963-1969.
DOI WoS46 Europe PMC26
2008 Juhasz, A. L., Smith, E. R. G., Weber, J., Naidu, R., Rees, M., Rofe, A., . . . Sansom, L. N. (2008). Effect of soil ageing on in vivo arsenic bioavailability in two dissimilar soils. Chemosphere, 71(11), 2180-2186.
DOI WoS58 Europe PMC34
2007 Roughead, E. E., Lopert, R., & Sansom, L. N. (2007). International price comparisons for novel and follow-on drugs: a response. Value in Health, 10(6), 512-513.
DOI
2007 Roughead, E. E., Lopert, R., & Sansom, L. N. (2007). Prices for innovative pharmaceutical products that provide health gain : a comparison between Australia and the United States. Value in Health, 10(6), 514-520.
DOI
2007 Sansom, L. N. (2007). Future healthcare delivery - where is pharmacy?. Journal of Pharmacy Practice and Research.
2007 Juhasz, A., Smith, E., Weber, J., Rees, M., Rofe, A., Kuchel, T., . . . Naidu, R. (2007). In vitro assessment of arsenic bioaccessibility in contaminated (anthropogenic and geogenic) soils. Chemosphere, 69(1), 69-78.
DOI WoS122 Europe PMC76
2007 Juhasz, A., Smith, E., Weber, J., Rees, M., Rofe, A., Kuchel, T., . . . Naidu, R. (2007). Comparison of in vivo and in vitro methodologies for the assessment of arsenic bioavailability in contaminated soils. Chemosphere, 69(6), 961-966.
DOI WoS117 Europe PMC95
2006 Juhasz, A., Smith, E., Weber, J., Rees, M., Rofe, A., Kuchel, T., . . . Naidu, R. (2006). In vivo assessment of arsenic bioavailability in rice and its significance for human health risk assessment. Environmental Health Perspectives, 114(12), 1826-1831.
DOI Scopus247 WoS220 Europe PMC137
2004 Sansom, L. N. (2004). The subsidy of pharmaceuticals in Australia: processes and challenges. Australian Health Review.
2004 Lu, C., Williams, K., Day, R., March, L., Sansom, L. N., & Bertouch, J. (2004). Access to high cost drugs in Australia. British Medical Journal, 329(7463), 415-416.
DOI
2004 Sansom, L. N., Lu, C., Williams, K., March, L., Bertouch, J., & Day, R. (2004). Subsidised access to TNFa inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?. Medical Journal of Australia.
2002 Sansom, L. N., Hiller, J., Anderson, J., Silagy, C., & Bessell, T. (2002). Quality of Global E-Pharmacies. European Journal of Clinical Pharmacology.
2002 Bessell, T., Anderson, J., Hiller, J., & Sansom, L. (2002). Medicines and the Internet: a qualitative study of the views and experiences of online medicine information seekers. Australian Pharmacist, 21(5), 361-365.
2002 Bessell, T., Silagy, C., Anderson, J., Hiller, J., & Sansom, L. (2002). Prevalence of South Australia's online health seekers. Australian and New Zealand Journal of Public Health, 26(2), 170-173.
DOI Scopus31 WoS22 Europe PMC18
2002 Bessell, T., McDonald, S., Silagy, C., Anderson, J., Hiller, J., & Sansom, L. (2002). Do Internet interventions for consumers cause more harm than good? A systematic review. Health Expectations, 5(1), 28-37.
DOI Scopus139 Europe PMC83
2002 Gilbert, A. L., Roughead, E. E., & Sansom, L. N. (2002). I've missed a dose; What should I do?. Australian Prescriber.
2000 Jones, J., Cheek, J., Gilbert, A. L., Sansom, L. N., Ballantyne, A., & Penhall, R. (2000). Quality use of medicines in residential aged care: linking research with policy through collaborative multidisciplinary partnerships. Australasian journal on ageing.
1999 Bessell, T., Hiller, J., & Sansom, L. (1999). Pharmacist only' medicines. Australian and New Zealand Journal of Public Health, 23(6), 661-662.
DOI Scopus13 WoS11 Europe PMC7
1999 Sansom, L. N. (1999). Oral extended release products. Australian prescriber.
1999 Sansom, L. N. (1999). The Australian National Medicinal Drug Policy. Journal for Quality in Clinical Practice.
1998 Sansom, L. N. (1998). Hospital Pharmacy Practice - Its place in the future. Australian journal of hospital pharmacy.
1998 Roughead, E. E., Gilbert, A. L., Primrose, J., & Sansom, L. N. (1998). Coding drug-related admissions in medical records: Is it adequate for monitoring the quality of medicine use.. Australian journal of hospital pharmacy.
1998 Sansom, L. N., Kostewicz, E. S., Kuchel, T., & Morella, A. (1998). Biopharmaceutical Evaluation of Nifedipine Controlled Release (CR) Products in the Pig.. European Journal of Pharmaceutical Sciences.
1998 Roughead, E. E., Gilbert, A. L., Primrose, J., & Sansom, L. N. (1998). Drug-related hospital admissions. Medical journal of Australia.
1996 Rowett, D., Latimer, K., Sansom, L., Ruffin, R., May, F., Henderson, G., & Hayball, P. (1996). The effect of hypoxaemia on drug disposition in chronic respiratory failure. European Journal of Clinical Pharmacology, 50(1), 77-82.
DOI Scopus3 WoS2 Europe PMC1
1995 Sansom, L. N., & Evans, A. M. (1995). What is the true clinical significance of plasma-protein binding displacement interactions. Drug Safety, 12(4), 227-233.
DOI Scopus85 WoS69 Europe PMC51
1993 Hayball, P. J., Nation, R. L., Bochner, F., Sansom, L. N., Ahern, M. J., & Smith, M. D. (1993). The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology, 36(3), 185-193.
DOI Scopus37 Europe PMC25
1993 Gilbert, A., Innes, J. M., Owen, N., & Sansom, L. (1993). Trial of an intervention to reduce chronic benzodiazepine use among residents of aged-care accommodation. Australian and new zealand journal of medicine, 23(4), 343-347.
DOI
1991 Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1991). Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen.. British journal of clinical pharmacology, 31(2), 131-138.
DOI Scopus52 WoS56 Europe PMC36
1989 Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1989). Stereoselective plasma protein binding of ibuprofen enantiomers. European journal of clinical pharmacology, 36(3), 283-290.
DOI Scopus93 WoS91 Europe PMC68
1989 Evans, A. M., Nation, R. L., & Sansom, L. N. (1989). Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. British journal of clinical pharmacology, 28(2), 132-149.
DOI Scopus21 WoS23 Europe PMC16
1988 Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1988). Stereoselective drug disposition: potential for misinterpretation of drug disposition data. British journal of clinical pharmacology, 26(6), 771-780.
DOI Scopus58 WoS53 Europe PMC47
1979 Sansom, L. N., Milne, R. W., & Cooper, D. (1979). Comparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tablets. European journal of clinical pharmacology, 16(6), 417-421.
DOI

Year Citation
2010 Sansom, L. N. (2010). Pharmacists, Pharmacovigilance, Unapproved Indications and the TGA. In Journal of Pharmacy Practice and Research Vol. 40 (pp. 88-89). Australia: Society of Hospital Pharmacists of Australia.
2008 Smith, E. R. G., Juhasz, A. L., Weber, J., Naidu, R., Rees, M., Rofe, A., . . . Sansom, L. N. (2008). Arsenic speciation and its impacts on human health bioavailability. In Proceedings of the 6th International Conference on Remediation of chlorinated and Recalcitrant Compounds. California: Battelle.
2003 Bessell, T., Anderson, J., Silagy, C., Sansom, L., & Hiller, J. (2003). Surfing, self-medicating and safety: buying non-prescription and complementary medicines via the internet. In Quality and Safety in Health Care Vol. 12 (pp. 88-92). England: British Med Journal Publ Group.
DOI Scopus74 WoS57 Europe PMC40
2000 Sansom, L. N., Bessell, T., & Hiller, J. (2000). 'Pharmacist only medicines': A pilot study monitoring the public health issues.. In AAPA/PAC Conference.
2000 Gilbert, A. L., Sansom, L. N., Cheek, J., Ballantyne, A., Penhall, R., & Jones, J. (2000). Quality Use of Medicines in Residential Aged Care: Issues Affecting the Implementation of Best Practice Guidelines. In FAPA/PAC Conference.
1998 Roughead, E. E., Gilbert, A. L., Primrose, J., & Sansom, L. N. (1998). Quality Use of medicines in Australia: How far have we come and where are we going?. In Proceedings of ASCEPT. ASCEPT.
1998 Lu, M. V., Fishlock, R. C., Kostewicz, E. S., Sansom, L. N., & Kuchel, T. (1998). Biopharmaceutic evaluation of a Diclofenac product in the pig. In Proceedings of ASCEPT. Australia: ASCEPT.
1997 Sansom, L. N., Gilbert, A. L., Primrose, J., & Roughead, E. E. (1997). The development of outcome indicators for Australia's policy on the quality use of medicines. In Conference Proceedings: Austalasian Pharmaceutical Sciences Association.

Connect With Me

Other Links